Messinger D - Search Results

1

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Sterling RK, et al. Among authors: messinger d. Hepatology. 2006 Jun;43(6):1317-25. doi: 10.1002/hep.21178. Hepatology. 2006. PMID: 16729309

2

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.

Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Bruno S, et al. Among authors: messinger d. Hepatology. 2010 Feb;51(2):388-97. doi: 10.1002/hep.23340. Hepatology. 2010. PMID: 19918980 Clinical Trial.

3

Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B.

Marcellin P, Martinot-Peignoux M, Asselah T, Batrla R, Messinger D, Rothe V, Lau G, Liaw YF. Marcellin P, et al. Among authors: messinger d. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1532-9.e1. doi: 10.1016/j.cgh.2014.12.017. Epub 2014 Dec 24. Clin Gastroenterol Hepatol. 2015. PMID: 25542306

4

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Fried MW, et al. Among authors: messinger d. J Hepatol. 2011 Jul;55(1):69-75. doi: 10.1016/j.jhep.2010.10.032. Epub 2010 Nov 23. J Hepatol. 2011. PMID: 21145856 Clinical Trial.

5

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.

Asselah T, Thompson AJ, Flisiak R, Romero-Gomez M, Messinger D, Bakalos G, Shiffman ML. Asselah T, et al. Among authors: messinger d. PLoS One. 2016 Mar 18;11(3):e0150569. doi: 10.1371/journal.pone.0150569. eCollection 2016. PLoS One. 2016. PMID: 26991780 Free PMC article.

6

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Marcellin P, et al. Among authors: messinger d. J Hepatol. 2012 Jun;56(6):1276-82. doi: 10.1016/j.jhep.2011.12.026. Epub 2012 Feb 4. J Hepatol. 2012. PMID: 22314423

7

An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings.

Lampertico P, Messinger D, Oladipupo H, Bakalos G, Castillo M, Asselah T. Lampertico P, et al. Among authors: messinger d. Antivir Ther. 2018;23(8):655-663. doi: 10.3851/IMP3251. Antivir Ther. 2018. PMID: 29972138

8

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.

Lee SS, Roberts SK, Berak H, Dusheiko GM, Harley HA, Gane EJ, Husa P, Horsmans YJ, Hadziyannis SJ, Jenny Heathcote E, Messinger D, Tatsch F, Han KH, Ferenci P. Lee SS, et al. Among authors: messinger d. Liver Int. 2012 Sep;32(8):1270-7. doi: 10.1111/j.1478-3231.2012.02819.x. Epub 2012 May 24. Liver Int. 2012. PMID: 22621707 Clinical Trial.

9

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.

Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M. Marcellin P, et al. Among authors: messinger d. Expert Opin Drug Saf. 2012 Nov;11(6):901-9. doi: 10.1517/14740338.2012.721927. Epub 2012 Sep 4. Expert Opin Drug Saf. 2012. PMID: 22943161

10

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.

Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Reddy KR, et al. Among authors: messinger d. J Viral Hepat. 2008 Feb;15(2):129-36. doi: 10.1111/j.1365-2893.2007.00901.x. J Viral Hepat. 2008. PMID: 18184196

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page